REVB

Revelation Biosciences Inc

Add to Watchlist

Advanced Chart

1.470

+0.01(0.685%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.690

Open

1.460

VWAP

1.56

Vol

747.99K

Mkt Cap

3.44M

Low

1.450

Amount

1.17M

EV/EBITDA(TTM)

Total Shares

1.63M

-1.76M

EV/OCF(TTM)

P/S(TTM)

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-1.000

-93.31%

-1.335

-96.69%

-6.150

-97.5%

Estimates Revision

The market is revising No Change the revenue expectations for Revelation Biosciences, Inc. (REVB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.43%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-41.43%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast REVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REVB is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.470

Low

20.00

Averages

20.00

High

20.00

Current: 1.470

Low

20.00

Averages

20.00

High

20.00

The End

No Data

Valuation Metrics

The current forward P/E ratio for Revelation Biosciences Inc (REVB.O) is -0.27, compared to its 5-year average forward P/E of -4.56. For a more detailed relative valuation and DCF analysis to assess Revelation Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.56

Current PE

-0.27

Overvalued PE

4.38

Undervalued PE

-13.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.37

Current PS

0.00

Overvalued PS

1.99

Undervalued PS

-1.25